<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Methods to overcome radiation resistance in head and neck cancer</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Methods to overcome radiation resistance in head and neck cancer</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Methods to overcome radiation resistance in head and neck cancer</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bruce E Brockstein, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Everett E Vokes, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David S Yoo, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marshall R Posner, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David M Brizel, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Melinda Yushak, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 09, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Radiation therapy (RT) plays a major role in the management of head and neck squamous cell carcinomas. Despite therapeutic and technological advances, some patients will have persistence of irradiated tumor or develop locoregional failure, resulting in significant morbidity and mortality [<a href="#rid1">1</a>]. Radioresistance is a broad term that describes the relative resistance of individual cells, tissues, organs, or entire organisms to the biologic effects of RT [<a href="#rid2">2</a>].</p><p>Mechanisms of radioresistance to RT in head and neck cancer and strategies used to overcome this resistance are discussed here. Concurrent chemoradiation is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/3392.html" rel="external">"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy"</a> and  <a class="medical medical_review" href="/z/d/html/3409.html" rel="external">"Definitive radiation therapy for head and neck cancer: Dose and fractionation considerations"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">MECHANISMS OF RADIORESISTANCE</span><span class="headingEndMark"> — </span>Many factors affect the responsiveness of tumors to radiation therapy (RT). Individual patients with tumors of similar size and stage can respond very differently to RT.</p><p>Relevant factors are related to the primary tumor (eg, volume, size, grade, human papillomavirus [HPV] status), the patient (eg, hemoglobin levels, smoking status), and biologic factors (eg, hypoxia, expression of DNA repair genes, alterations of many other genes, and proliferation status).</p><p class="headingAnchor" id="H3"><span class="h2">Clinical factors affecting radiation response</span></p><p class="headingAnchor" id="H4"><span class="h3">Primary tumor characteristics</span><span class="headingEndMark"> — </span>The complexity and variability of clinical outcomes in head and neck cancer are reflected in the spectrum of T stage descriptors used in the American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) tumor, node, metastasis (TNM) staging system for the different primary sites [<a href="#rid3">3</a>]. Larger tumors and/or those with more extensive local invasion have higher T classifications, corresponding to a likely higher malignant cell burden and poorer prognosis. Larger tumors are also more likely to harbor biological factors associated with treatment resistance. (See  <a class="medical medical_review" href="/z/d/html/3393.html" rel="external">"Overview of the diagnosis and staging of head and neck cancer"</a>.)</p><p>Radiation-related cell killing is a random event; the potentially lethal DNA double-strand breaks induced by irradiation are distributed randomly throughout the radiation-sensitive cells and will not kill all cells. As tumor burden increases, the probability of lethally damaging all of the cancer cells decreases, even if the total dose is escalated to high levels.</p><p>The location of the primary tumor site may influence response to therapy. As an example, oral cavity tumors demonstrate poorer response to RT than laryngeal tumors [<a href="#rid4">4</a>]. Tumor grade may also play a role. Well-differentiated tumors, which retain the ability to accelerate repopulation during RT, are characteristically more radioresistant than their moderately and poorly differentiated counterparts [<a href="#rid5">5</a>]. (See <a class="local">'Repopulation'</a> below.)</p><p class="headingAnchor" id="H17473763"><span class="h3">Inherent tumor cell radioresistance</span><span class="headingEndMark"> — </span>Differences in intrinsic tumor cell radiosensitivity are seen experimentally and may contribute significantly to radiation failure [<a href="#rid6">6,7</a>]. Head and neck cancers associated with the HPV have an improved prognosis relative to their HPV-negative counterparts, most likely due to their enhanced sensitivity to chemotherapy and radiation. (See  <a class="medical medical_review" href="/z/d/html/3378.html" rel="external">"Epidemiology, staging, and clinical presentation of human papillomavirus associated head and neck cancer"</a>.)</p><p class="headingAnchor" id="H17473817"><span class="h2">Patient factors</span></p><p class="headingAnchor" id="H5"><span class="h3">Hemoglobin</span><span class="headingEndMark"> — </span>Lower pretreatment hemoglobin levels (&lt;14.5 g/dL for males and &lt;13 g/dL for females) are correlated with reduced local control and survival in patients with head and neck cancer [<a href="#rid8">8,9</a>]. However, the relationship between hemoglobin concentration, tumor oxygenation status, and radioresistance is complex. Most anemic patients have tumors that are hypoxic, but the absence of anemia does not ensure that a tumor will be well oxygenated.</p><p class="headingAnchor" id="H6"><span class="h3">Smoking status</span><span class="headingEndMark"> — </span>Patients with head and neck cancer who continue to smoke during RT have lower rates of response and survival than patients who do not smoke during RT [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H7"><span class="h2">Biological factors determining radiation response</span></p><p class="headingAnchor" id="H8"><span class="h3">Hypoxia</span><span class="headingEndMark"> — </span>The high-energy photons used in RT exert their biologic effects via secondary electrons generated in tissue through a process known as the Compton effect [<a href="#rid11">11</a>]. These secondary electrons induce DNA damage through both direct and indirect actions. With direct action, the electrons interact with and ionize atoms of the DNA helix. With indirect action, the electrons first ionize molecules around the DNA, such as water, producing highly reactive free radical species that then interact with and damage DNA. Unrepaired DNA damage leads to inhibition of cell proliferation, fatal chromosomal aberrations, and cell death. For photon radiation, the indirect mechanism predominates [<a href="#rid2">2</a>].</p><p>The presence of oxygen enhances the indirect process by prolonging the life span of the highly reactive free radicals generated by indirect ionization. Additionally, oxygen decreases the ability of cells to repair sublethal DNA damage, reacting with the broken ends of DNA to create stable organic peroxides that are not as readily repaired [<a href="#rid12">12</a>]. Well-oxygenated cells are two and one-half to three times more radiosensitive than hypoxic cells (oxygen partial pressure [pO<sub>2</sub>] &lt;10 mmHg), a relationship described by the oxygen enhancement ratio (OER): the ratio of RT doses needed in hypoxic versus aerobic conditions to achieve the same biologic effect.</p><p>Intratumor hypoxia can be chronic, arising as the tumor outgrows the limits of its blood supply, or acute, when there is a disruption in microregional blood flow [<a href="#rid13">13</a>]. Tumor hypoxia in head and neck cancer correlates with radioresistance and is an adverse prognostic factor [<a href="#rid14">14,15</a>]. In one report, patients with a median tumor pO<sub>2</sub> &gt;10 mmHg, compared with those with tumor pO<sub>2</sub> levels &lt;10 mmHg, had significantly better two-year local control (82 versus 41 percent), disease-free survival (70 versus 31 percent), and overall survival (80 versus 46 percent) [<a href="#rid14">14</a>].</p><p>Other biologic mechanisms also modulate the link between hypoxia and radiosensitivity [<a href="#rid12">12</a>]. Many signaling pathways are impacted by hypoxia, including those involved in angiogenesis, glucose transport, pH regulation, and erythropoiesis [<a href="#rid16">16</a>]. </p><p>As an example, the hypoxia-inducible factor (HIF) family of transcription factors plays an important role in the cellular response to oxygen homeostasis in vivo. HIF-1 alpha overexpression is seen in over one-half of all head and neck cancers and correlates with poor response to RT [<a href="#rid17">17,18</a>]. Overexpression of the HIF-1-regulated hypoxia-related protein lysyl oxidase is associated with increased metastases, progression, and death in patients with head and neck cancer [<a href="#rid19">19,20</a>]. However, there is also evidence that HIF-1 inhibition may both suppress and enhance the effects of RT [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H9"><span class="h3">Repopulation</span><span class="headingEndMark"> — </span>Repopulation is defined as regrowth of tumor cells after the initiation of RT [<a href="#rid22">22</a>]. Accelerated tumor cell repopulation is an important factor contributing to the radioresistance of head and neck cancer [<a href="#rid23">23</a>]. Potential mechanisms include accelerated stem cell division, loss in asymmetrical division, and cell recruitment [<a href="#rid24">24</a>].</p><p>Accelerated stem cell division describes the shortening of the cell cycle after the start of RT. Loss in asymmetry refers to the shift in stem cells from asymmetric division, which produces one stem cell and one progenitor cell with limited self-renewal potential, to symmetric division, which gives rise to two identical stem cells. Lastly, quiescent cells in G0 phase may be recruited to re-enter more-active phases of the cell cycle.</p><p>Cyclins, cyclin inhibitors, Ki-67, and the epidermal growth factor receptor (EGFR) may all serve as markers of tumor proliferation [<a href="#rid16">16</a>]. Expression of Ki-67 and EGFR has been associated with radioresistance and has been studied to select patients for and predict response to regimens aimed to overcome repopulation, such as accelerated RT or anti-EGFR therapy [<a href="#rid22">22,25,26</a>].</p><p class="headingAnchor" id="H10"><span class="h3">Inherent tumor cell radioresistance</span><span class="headingEndMark"> — </span>Differences in intrinsic tumor cell radiosensitivity are seen experimentally and may contribute significantly to radiation failure [<a href="#rid6">6,7</a>]. Head and neck cancers associated with HPV have an improved prognosis relative to HPV-negative tumors. There are some data to suggest that the better prognosis of these tumors may be attributable to their enhanced sensitivity to chemotherapy and radiation. (See  <a class="medical medical_review" href="/z/d/html/3378.html" rel="external">"Epidemiology, staging, and clinical presentation of human papillomavirus associated head and neck cancer"</a>.)</p><p class="headingAnchor" id="H11"><span class="h3">Cancer stem cells</span><span class="headingEndMark"> — </span>The potential role of cancer stem cells in radioresistance has been demonstrated in an increasing number of solid cancers [<a href="#rid27">27-30</a>]. If not eliminated by RT, stem cells have the capacity to self-renew and differentiate into the heterogeneous cells that constitute a tumor mass [<a href="#rid31">31,32</a>]. Experimental evidence suggests that a higher proportion of cancer stem cells within a tumor correlates with higher radioresistance [<a href="#rid33">33</a>]. Furthermore, cancer stem cells have been shown to possess inherent resistance mechanisms, such as amplified checkpoint activation and DNA damage repair [<a href="#rid34">34</a>]. Extrinsic factors, such as hypoxia, may also impact the radioresistance of cancer stem cells [<a href="#rid35">35</a>].</p><p class="headingAnchor" id="H12"><span class="h3">Other factors</span><span class="headingEndMark"> — </span>Radioresistance may also occur as a consequence of other biologic factors: amplification of DNA repair genes, increased cellular production of free radical scavengers (eg, glutathione), activation of certain protooncogenes, and stromal interactions [<a href="#rid7">7</a>].</p><p>As an example, the excision repair cross-complementation group 1 protein (ERCC1) is a drug-resistance-related DNA repair protein that prevents apoptosis of cancer cells by removing platinum-DNA adducts generated by <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>. ERCC1 may also play a role in the repair of radiation-induced DNA damage. High expression of ERCC1 in nasopharyngeal cancer patients has been associated with poor survival after concurrent chemoradiation [<a href="#rid36">36</a>]. In addition, cells with a mutated p53 tumor suppressor gene fail to arrest at the G1/S cell cycle checkpoint following irradiation and are less likely to undergo apoptosis [<a href="#rid37">37</a>]. Similarly, overexpression of survivin, an oncogene of the inhibitor of apoptosis (IAP) family, may contribute to treatment resistance via negative regulation of programmed cell death and enhanced DNA repair [<a href="#rid38">38</a>].</p><p>Radioresistance involves a complex interplay between biologic processes. Investigators are applying genomics, proteomics, and gene expression profiling techniques to identify new targets and novel interactions.</p><p class="headingAnchor" id="H13"><span class="h1">STRATEGIES TO OVERCOME RADIORESISTANCE</span><span class="headingEndMark"> — </span>Multiple strategies have been developed and tested in randomized clinical trials to improve the clinical results obtained with conventional radiation therapy (RT) given alone.</p><p class="headingAnchor" id="H17474013"><span class="h2">Altered fractionation RT</span><span class="headingEndMark"> — </span>RT regimens using accelerated fractionation schedules can shorten the overall treatment duration, thereby attempting to minimize tumor repopulation as a cause of treatment failure. Pure hyperfractionation regimens, by treating twice daily with smaller fraction sizes, permit a higher total radiation dose without increasing late toxicity. Late effects on normal tissues are influenced by the individual dose fraction size. Altered fractionation strategies are discussed separately.</p><p>The clinical application of altered fractionation schedules is discussed separately, as are the applications of these approaches with concurrent chemotherapy. (See  <a class="medical medical_review" href="/z/d/html/3409.html" rel="external">"Definitive radiation therapy for head and neck cancer: Dose and fractionation considerations", section on 'Accelerated fractionation RT'</a> and  <a class="medical medical_review" href="/z/d/html/3409.html" rel="external">"Definitive radiation therapy for head and neck cancer: Dose and fractionation considerations", section on 'Hyperfractionation'</a> and  <a class="medical medical_review" href="/z/d/html/3392.html" rel="external">"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy", section on 'Radiation therapy treatment plan'</a>.)</p><p class="headingAnchor" id="H262962680"><span class="h2">Concurrent systemic therapy</span></p><p class="headingAnchor" id="H262963170"><span class="h3">Chemotherapy</span><span class="headingEndMark"> — </span>Concurrent chemoradiation exploits the additive and synergistic effects that result when chemotherapy and RT are used together. Preclinical studies suggest that many chemotherapeutic agents contribute to improved outcomes through additive effects, via the independent cytotoxic action of the drugs themselves as well as through synergistic effects in which the drugs alter cell radiosensitivity.</p><p>Chemotherapy agents with radiosensitizing properties in vitro include <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>, <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a>, <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a>, <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a>, <a class="drug drug_general" data-topicid="9658" href="/z/d/drug information/9658.html" rel="external">mitomycin</a>, <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a>, <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">bleomycin</a>, <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a>, and <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a>. Many mechanisms have been proposed to explain how the addition of chemotherapy augments the effects of RT [<a href="#rid39">39,40</a>]. These include:</p><p class="bulletIndent1"><span class="glyph">●</span>Making DNA more susceptible to radiation damage and augmenting cell killing</p><p class="bulletIndent1"><span class="glyph">●</span>Interfering with cellular DNA repair after sublethal or potentially lethal damage (<a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> and <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Reducing tumor cell repopulation by enhancing the cytotoxic effect (<a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> and <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Reducing the population of hypoxic tumor cells (<a class="drug drug_general" data-topicid="9658" href="/z/d/drug information/9658.html" rel="external">mitomycin</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Exerting cytotoxic effects in the radioresistant S phase (camptothecins)</p><p class="bulletIndent1"><span class="glyph">●</span>Redistribution and accumulation of cells into the more radiosensitive G2 and M phases (<a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a> and <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Promoting apoptosis</p><p class="bulletIndent1"><span class="glyph">●</span>Inhibiting angiogenesis</p><p></p><p>Concurrent chemoradiation improves locoregional control and survival compared with RT alone for head and neck cancer patients with unresectable disease and for those in whom a functional organ preservation strategy provides a nonsurgical alternative for cure while maintaining quality of life [<a href="#rid1">1</a>]. To date, concurrent chemoradiation remains the most effective strategy, as attempts to add various other agents to chemoradiation have not consistently resulted in improved outcomes compared with chemoradiation alone. (See  <a class="medical medical_review" href="/z/d/html/3392.html" rel="external">"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy"</a>.)</p><p class="headingAnchor" id="H262963057"><span class="h3">Molecularly targeted agents</span><span class="headingEndMark"> — </span>Molecularly targeted agents may potentiate the effects of radiation by targeting specific cell signaling pathways involved with radioresistance.</p><p><a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">Cetuximab</a>, a monoclonal antibody directed against the epidermal growth factor receptor (EGFR), inhibits tumor proliferation and has been shown to improve locoregional control and overall survival in combination with RT alone. However, in HPV associated oropharyngeal cancer, cetuximab plus chemoradiation has inferior survival outcomes compared with cisplatin-based chemoradiation. These data are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3392.html" rel="external">"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy", section on 'Cetuximab plus radiation therapy'</a>.)</p><p>Several other novel agents including some that are in preclinical or early clinical investigation target key components of various signaling pathways, including those for angiogenesis (vascular endothelial growth factor [VEGF]), DNA repair (poly adenosine diphosphate ribose polymerase [PARP]) and apoptosis, hypoxia (hypoxia-inducible factor 1 [HIF-1]), and proliferation (PI3-kinase/AKT) [<a href="#rid41">41-44</a>].</p><p class="headingAnchor" id="H310529108"><span class="h3">Checkpoint inhibitor immunotherapy</span><span class="headingEndMark"> — </span>The programmed cell death receptor 1 (PD-1) inhibitor drugs <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> and <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> are approved for use in patients with unresectable or metastatic squamous head and neck cancer. (See  <a class="medical medical_review" href="/z/d/html/3364.html" rel="external">"Treatment of metastatic and recurrent head and neck cancer", section on 'PD-1 inhibitor immunotherapy'</a>.) </p><p>Uncontrolled data, especially in melanoma, have suggested a potential synergistic effect with immunotherapy given together with RT, both in the radiation-targeted tumor and at other sites. However, there are no randomized trial data supporting the combination of checkpoint inhibitor immunotherapy and RT in patients with squamous cell carcinoma of the head and neck. For example, a randomized phase III trial (JAVELIN Head and Neck 100) evaluating the addition of the programmed-death ligand 1 (PD-L1) inhibitor <a class="drug drug_general" data-topicid="112481" href="/z/d/drug information/112481.html" rel="external">avelumab</a> to standard-of-care definitive chemoradiation in this population was terminated because the combination was unlikely to achieve an improvement in progression-free survival [<a href="#rid45">45,46</a>].</p><p class="headingAnchor" id="H262962536"><span class="h1">OTHER APPROACHES</span><span class="headingEndMark"> — </span>A number of other approaches have been studied clinically in an effort to overcome the radiation response observed clinically.</p><p class="headingAnchor" id="H19"><span class="h2">Targeting hypoxia</span><span class="headingEndMark"> — </span>Hypoxia may be an important contributor to radiation resistance. Several different strategies have been aimed at reducing the effects of hypoxia on radiation resistance. None of these has achieved widespread clinical utilization. (See <a class="local">'Hypoxia'</a> above.)</p><p class="headingAnchor" id="H262963472"><span class="h3">Hypoxic cell sensitizers</span><span class="headingEndMark"> — </span>The most extensively studied agents are the hypoxic cell sensitizers or oxygen mimetics, including misonidazole, nimorazole, and other related compounds. These have been studied in numerous randomized trials in patients with head and neck cancer, most extensively in Europe.</p><p>A systematic review of the literature and meta-analysis combined results from 18 trials that included almost 3400 patients [<a href="#rid47">47</a>]. The addition of these agents significantly improved locoregional control and decreased disease-specific deaths (odds ratios [ORs] 0.76, 95% CI 0.66-0.88, and 0.74, 95% CI 0.64-0.86, respectively), although the difference in overall survival was not significant (OR 0.87, 95% CI 0.75-1.02, p = 0.08).</p><p>Clinical interest in these drugs has been hampered by their marginal efficacy as well as dose-limiting toxicities (eg, delayed peripheral neuropathy with misonidazole).</p><p class="headingAnchor" id="H17474137"><span class="h3">Hypoxic cell cytotoxins</span><span class="headingEndMark"> — </span>Tirapazamine is a hypoxic cell cytotoxic that selectively killed hypoxic cells in preclinical experiments and phase I to II studies, and potentiated the effects of radiation therapy (RT) and chemotherapy [<a href="#rid48">48</a>]. However, a large phase III trial failed to demonstrate a survival advantage for the addition of tirapazamine to RT and <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> [<a href="#rid49">49</a>]. A second phase III trial was closed early due to excess mortality when tirapazamine was combined with cisplatin plus RT [<a href="#rid50">50</a>].</p><p class="headingAnchor" id="H20"><span class="h3">Hyperbaric oxygen</span><span class="headingEndMark"> — </span>Hyperbaric oxygen therapy increases the amount of oxygen in the blood and has been studied in a variety of tumors [<a href="#rid51">51</a>]. The amount of dissolved plasma oxygen is 0.3 mL/dL at 1.0 atmosphere; this is increased to 1.5 mL/dL upon administration of 100 percent oxygen and to 6 mL/dL with hyperbaric oxygen delivered at 3.0 atmosphere. Despite this theoretical advantage, studies using hyperbaric oxygen during RT for head and neck cancer have been disappointing. Because of the lack of clear benefit, the difficulty of completing combined RT and hyperbaric oxygen together, and other more effective alternatives, hyperbaric oxygen is generally not used clinically.</p><p>A systemic review and meta-analysis that included nine trials with 624 patients found that hyperbaric oxygen significantly improved locoregional control and decreased disease-specific deaths (ORs 0.46, 95% CI 0.33-0.64, and 0.58, 95% CI 0.42-0.81, respectively), although the difference in overall survival was not statistically significant (OR 0.73, 95% CI 0.51-1.05, p = 0.09) [<a href="#rid47">47</a>]. This approach is not used outside of clinical trials.</p><p class="headingAnchor" id="H262963905"><span class="h3">Functional imaging</span><span class="headingEndMark"> — </span>Radiographic studies, such as dynamic contrast-enhanced magnetic resonance imaging (MRI) and hypoxia-specific positron emission tomography (PET) scans, can noninvasively and indirectly measure tumor hypoxia [<a href="#rid52">52-54</a>]. Work is ongoing to establish reproducible and relevant imaging correlations that can guide future clinical decision making. With their ability to capture and display regional differences in hypoxia within tumors, these imaging modalities provide potential physical targets for radiation dose escalation via highly conformal RT delivery technologies [<a href="#rid55">55,56</a>]. However, serial imaging has shown day-to-day variability in the spatial distribution of tumor hypoxia [<a href="#rid57">57</a>]. Moving targets can be missed and, thus, may be a source of local failure.</p><p class="headingAnchor" id="H23"><span class="h2">Correction of anemia</span><span class="headingEndMark"> — </span>Correction of asymptomatic anemia, with either transfusion or the use of erythropoiesis-stimulating agents, has been postulated to decrease tumor hypoxia and reduce radioresistance, and thereby, improve clinical outcomes. However, there is no direct evidence to support these approaches.</p><p class="headingAnchor" id="H262963824"><span class="h3">Transfusion</span><span class="headingEndMark"> — </span>Transfusion prior to and during treatment failed to improve outcome in patients with low hemoglobin levels in the Danish Head and Neck Cancer (DAHANCA) 5 study [<a href="#rid58">58</a>]. In this trial, patients were randomly assigned to the hypoxic radiosensitizer nimorazole or to placebo. In addition, 171 patients with low hemoglobin levels (females &lt;13 g/dL and males &lt;14.5 g/dL) were randomly assigned to transfusion or not. Although transfusion increased hemoglobin levels for most patients, receipt of transfusion did not improve locoregional control, disease-specific survival, or overall survival (hazard ratios [HRs] 0.99, 1.07, and 1.10, respectively). Correction of baseline anemia might improve efficacy of RT in the subset of patients with more-severe anemia, but there is limited evidence to support this approach.</p><p class="headingAnchor" id="H262963844"><span class="h3">Erythropoiesis-stimulating agents</span><span class="headingEndMark"> — </span>Erythropoiesis-stimulating agents can reduce chemotherapy-induced anemia and the need for transfusions in head and neck cancer patients [<a href="#rid59">59,60</a>]. Retrospective data demonstrated that erythropoiesis-stimulating agents used prior to or during chemoradiation in oral cavity and oropharyngeal tumors corrected anemia and overcame the adverse prognostic effect of low pretreatment hemoglobin levels [<a href="#rid61">61</a>]. However, subsequent prospective trials have failed to confirm a clinical benefit from this approach. In fact, many trials were closed based upon interim analyses due to consistently worse outcomes in patients who received erythropoiesis-stimulating agents during therapy [<a href="#rid62">62-66</a>].</p><p>As an example, in one of the largest of these trials, 522 patients with squamous cell carcinoma in the head and neck were randomly assigned to weekly <a class="drug drug_general" data-topicid="8662" href="/z/d/drug information/8662.html" rel="external">darbepoetin alfa</a> or placebo weekly during RT in the DAHANCA-10 trial [<a href="#rid66">66</a>]. All patients had an initial hemoglobin value less than 14.0 g/dL, and treatment was continued until the hemoglobin value was 15.5 g/dL. The trial was terminated after a planned interim analysis because of the inferiority of the active treatment regimen. The five-year rate of locoregional failure was significantly increased with darbepoetin alpha (47 versus 34 percent, HR 1.53, 95% CI 1.16-2.02). Similar statistically significant results were seen for event-free survival, disease-specific death, and overall survival.</p><p>A Cochrane review examined the use of erythropoiesis-stimulating agents with RT or chemoradiation in five trials with a total of 1397 head and neck cancer patients [<a href="#rid65">65</a>]. Of note, the target hemoglobin concentration was higher than recommended in four of the five trials. Significantly worse overall survival was seen in the patients who received an erythropoiesis-stimulating agent (OR 0.73, 95% CI 0.58-0.91, p = 0.005).</p><p>Reasons for the adverse outcomes associated with the use of erythropoiesis-stimulating agents during RT are unclear. These trials attempted to correct hemoglobin concentration to supraphysiologic levels, and it has been suggested that an excess of thromboembolic events may have contributed to the worse outcomes [<a href="#rid67">67</a>]. Erythropoiesis-stimulating agents may also promote tumor progression, as erythropoietin receptors are expressed in head and neck cancer cell lines [<a href="#rid68">68</a>]. A follow-up analysis of samples from a phase III trial found that increased expression of the erythropoietin receptor was associated with a poorer local progression-free survival [<a href="#rid69">69</a>].</p><p>The issues surrounding the use of erythropoiesis-stimulating agents in cancer patients are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/2799.html" rel="external">"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer"</a>.)</p><p>Until 2017, the US Food and Drug Administration (FDA) required all erythropoiesis-stimulating agents to be prescribed and used under a risk evaluation and mitigation strategy (REMS) with clear understanding by treating clinicians and patients of the poorer survival, increased risk of treatment failure, and life-threatening side effects associated with their use [<a href="#rid70">70</a>]. While an REMS is no longer required, careful consideration should be given prior to starting these drugs in all patients. Transfusion remains an acceptable option to treat anemia in patients with head and neck cancer undergoing RT.</p><p class="headingAnchor" id="H25"><span class="h2">Radioprotectors</span><span class="headingEndMark"> — </span>The concomitant administration of a systemic agent that protects normal tissues from the effects of irradiation may reduce treatment-related toxicity, potentially allowing for the use of higher RT doses to overcome radioresistance.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8533" href="/z/d/drug information/8533.html" rel="external">Amifostine</a>, a thiol-containing compound that may act as a free radical scavenger, has been shown to reduce the risk of xerostomia in head and neck cancer patients treated with RT alone; its role in combination with chemoradiation and the higher doses of radiation used in contemporary treatment regimens remains uncertain. (See  <a class="medical medical_review" href="/z/d/html/3408.html" rel="external">"Management and prevention of complications during initial treatment of head and neck cancer", section on 'Amifostine'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10161" href="/z/d/drug information/10161.html" rel="external">Palifermin</a>, a recombinant keratinocyte growth factor, significantly decreased the incidence of severe mucositis in randomized trials in patients with head and neck cancer [<a href="#rid71">71,72</a>]. (See  <a class="medical medical_review" href="/z/d/html/3408.html" rel="external">"Management and prevention of complications during initial treatment of head and neck cancer", section on 'Palifermin'</a>.)</p><p></p><p>Neither <a class="drug drug_general" data-topicid="10161" href="/z/d/drug information/10161.html" rel="external">palifermin</a> nor <a class="drug drug_general" data-topicid="8533" href="/z/d/drug information/8533.html" rel="external">amifostine</a> has an established role in conjunction with the use of higher doses of radiation to try to overcome radioresistance and risk of locoregional failure in patients with head and neck cancer.</p><p class="headingAnchor" id="H262963571"><span class="h2">Hyperthermia</span><span class="headingEndMark"> — </span>Hyperthermia involves the heating of tissues to supraphysiologic temperatures; its concurrent use with RT may enhance the tumor response to radiation via additive and synergistic mechanisms [<a href="#rid73">73-75</a>].</p><p>The independent cytotoxic effects of hyperthermia are complementary to RT. Cells in S phase, the most radioresistant part of the cell cycle, are the most sensitive to hyperthermia [<a href="#rid76">76,77</a>]. Moreover, unlike RT, hypoxic conditions may also make cells more sensitive to hyperthermia [<a href="#rid78">78</a>]. Synergistic radiosensitization by hyperthermia may occur via inhibition of DNA repair pathways [<a href="#rid79">79,80</a>]. Finally, at more moderate temperatures, hyperthermia can improve blood flow, leading to increased perfusion, reoxygenation, and decreased hypoxia [<a href="#rid81">81</a>].</p><p>Two randomized trials in locally advanced head and neck squamous cell carcinoma patients showed improved tumor control with the use of hyperthermia concurrent with RT [<a href="#rid82">82,83</a>]. However, these trials were conducted in small numbers of patients using older techniques and dosing regimens, and their clinical relevance is uncertain.</p><p class="headingAnchor" id="H44803157"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/128559.html" rel="external">"Society guideline links: Head and neck cancer"</a>.)</p><p class="headingAnchor" id="H26"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanisms of radioresistance</strong> – Multiple clinical and biologic factors contribute to the development of radioresistance, which remains a significant obstacle to optimal locoregional disease control in patients with squamous cell carcinomas of the head and neck. Large tumors, continued smoking, and pretreatment anemia are clinical factors that have been inversely correlated with locoregional control. Tumor hypoxia, repopulation, cancer stem cells, and inherent differences in tumor cell radiosensitivity are biologic factors that have been identified as strongly correlating with radioresistance. In particular, human papilloma virus (HPV) status has emerged as a significant prognostic factor and predictor of response to radiation therapy (RT) in head and neck cancer. (See <a class="local">'Mechanisms of radioresistance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rationale for concurrent chemoradiation</strong> – Concurrent chemoradiation is the standard of care to decrease radioresistance and improve outcomes in patients who are treated with RT for head and neck cancer. Concurrent chemoradiation improves locoregional control and survival compared with RT alone for head and neck cancer patients with unresectable disease and for those in whom a functional organ preservation strategy provides a nonsurgical alternative for cure while maintaining quality of life. (See  <a class="medical medical_review" href="/z/d/html/3392.html" rel="external">"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Strategies to further intensify treatment beyond concurrent chemotherapy with conventionally fractionated RT have not demonstrated improved outcomes in unselected patient populations. Recognition of the influence of HPV status in treatment response has led to the design of clinical trials that separately investigate HPV-positive and HPV-negative patient populations. (See <a class="local">'Strategies to overcome radioresistance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Targeting hypoxia</strong> – Various approaches to target hypoxia have been evaluated in randomized clinical trials. Although these techniques may improve locoregional control, their clinical impact is less than that of concurrent chemoradiation, and they do not have a major role in the management of head and neck cancer patients. (See <a class="local">'Targeting hypoxia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>No role for</strong> <strong>erythropoietic agents during RT</strong> – We recommend <strong>against</strong> using erythropoietic agents to correct asymptomatic anemia during RT for head and neck cancer (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). Although the correction of anemia has a strong theoretical rationale, data do not support the routine use of transfusions or erythropoiesis-stimulating agents in patients with head and neck cancer, and these approaches may actually worsen outcomes. (See <a class="local">'Erythropoiesis-stimulating agents'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Blanchard P, Baujat B, Holostenco V, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. Radiother Oncol 2011; 100:33.</a></li><li class="breakAll">Hall EJ, Giaccia AJ. Radiobiology for the radiologist, 6th, Lippincott, Williams and Wilkins, Philadelphia 2006.</li><li class="breakAll">AJCC Cancer Staging Manual, Eighth, Amin, MB (Eds), Springer, Chicago 2017.</li><li><a class="nounderline abstract_t">Dinshaw KA, Agarwal JP, Ghosh-Laskar S, et al. Radical radiotherapy in head and neck squamous cell carcinoma: an analysis of prognostic and therapeutic factors. Clin Oncol (R Coll Radiol) 2006; 18:383.</a></li><li><a class="nounderline abstract_t">Hansen O, Overgaard J, Hansen HS, et al. Importance of overall treatment time for the outcome of radiotherapy of advanced head and neck carcinoma: dependency on tumor differentiation. Radiother Oncol 1997; 43:47.</a></li><li><a class="nounderline abstract_t">Gerweck LE, Vijayappa S, Kurimasa A, et al. Tumor cell radiosensitivity is a major determinant of tumor response to radiation. Cancer Res 2006; 66:8352.</a></li><li><a class="nounderline abstract_t">Ogawa K, Boucher Y, Kashiwagi S, et al. Influence of tumor cell and stroma sensitivity on tumor response to radiation. Cancer Res 2007; 67:4016.</a></li><li><a class="nounderline abstract_t">Lee WR, Berkey B, Marcial V, et al. Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85-27. Int J Radiat Oncol Biol Phys 1998; 42:1069.</a></li><li><a class="nounderline abstract_t">Prosnitz RG, Yao B, Farrell CL, et al. Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer. Int J Radiat Oncol Biol Phys 2005; 61:1087.</a></li><li><a class="nounderline abstract_t">Duffy SA, Ronis DL, McLean S, et al. Pretreatment health behaviors predict survival among patients with head and neck squamous cell carcinoma. J Clin Oncol 2009; 27:1969.</a></li><li><a class="nounderline abstract_t">Compton AH. On the Mechanism of X-Ray Scattering. Proc Natl Acad Sci U S A 1925; 11:303.</a></li><li><a class="nounderline abstract_t">Moeller BJ, Richardson RA, Dewhirst MW. Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. Cancer Metastasis Rev 2007; 26:241.</a></li><li><a class="nounderline abstract_t">Horsman MR. Nicotinamide and other benzamide analogs as agents for overcoming hypoxic cell radiation resistance in tumours. A review. Acta Oncol 1995; 34:571.</a></li><li><a class="nounderline abstract_t">Brizel DM, Sibley GS, Prosnitz LR, et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997; 38:285.</a></li><li><a class="nounderline abstract_t">Nordsmark M, Bentzen SM, Rudat V, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005; 77:18.</a></li><li><a class="nounderline abstract_t">Silva P, Homer JJ, Slevin NJ, et al. Clinical and biological factors affecting response to radiotherapy in patients with head and neck cancer: a review. Clin Otolaryngol 2007; 32:337.</a></li><li><a class="nounderline abstract_t">Aebersold DM, Burri P, Beer KT, et al. Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 2001; 61:2911.</a></li><li><a class="nounderline abstract_t">Winter SC, Shah KA, Han C, et al. The relation between hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression with anemia and outcome in surgically treated head and neck cancer. Cancer 2006; 107:757.</a></li><li><a class="nounderline abstract_t">Erler JT, Bennewith KL, Nicolau M, et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006; 440:1222.</a></li><li><a class="nounderline abstract_t">Le QT, Harris J, Magliocco AM, et al. Validation of lysyl oxidase as a prognostic marker for metastasis and survival in head and neck squamous cell carcinoma: Radiation Therapy Oncology Group trial 90-03. J Clin Oncol 2009; 27:4281.</a></li><li><a class="nounderline abstract_t">Harada H, Itasaka S, Zhu Y, et al. Treatment regimen determines whether an HIF-1 inhibitor enhances or inhibits the effect of radiation therapy. Br J Cancer 2009; 100:747.</a></li><li><a class="nounderline abstract_t">Tarnawski R, Fowler J, Skladowski K, et al. How fast is repopulation of tumor cells during the treatment gap? Int J Radiat Oncol Biol Phys 2002; 54:229.</a></li><li><a class="nounderline abstract_t">Withers HR, Taylor JM, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 1988; 27:131.</a></li><li><a class="nounderline abstract_t">Marcu L, van Doorn T, Olver I. Modelling of post-irradiation accelerated repopulation in squamous cell carcinomas. Phys Med Biol 2004; 49:3767.</a></li><li><a class="nounderline abstract_t">Bentzen SM, Atasoy BM, Daley FM, et al. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol 2005; 23:5560.</a></li><li><a class="nounderline abstract_t">Couture C, Raybaud-Diogène H, Têtu B, et al. p53 and Ki-67 as markers of radioresistance in head and neck carcinoma. Cancer 2002; 94:713.</a></li><li><a class="nounderline abstract_t">Baumann M, Krause M, Hill R. Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer 2008; 8:545.</a></li><li><a class="nounderline abstract_t">Dingli D, Michor F. Successful therapy must eradicate cancer stem cells. Stem Cells 2006; 24:2603.</a></li><li><a class="nounderline abstract_t">Milas L, Hittelman WN. Cancer stem cells and tumor response to therapy: current problems and future prospects. Semin Radiat Oncol 2009; 19:96.</a></li><li><a class="nounderline abstract_t">O'Brien CA, Kreso A, Dick JE. Cancer stem cells in solid tumors: an overview. Semin Radiat Oncol 2009; 19:71.</a></li><li><a class="nounderline abstract_t">Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006; 66:9339.</a></li><li><a class="nounderline abstract_t">Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea--a paradigm shift. Cancer Res 2006; 66:1883.</a></li><li><a class="nounderline abstract_t">Yaromina A, Krause M, Thames H, et al. Pre-treatment number of clonogenic cells and their radiosensitivity are major determinants of local tumour control after fractionated irradiation. Radiother Oncol 2007; 83:304.</a></li><li><a class="nounderline abstract_t">Eyler CE, Rich JN. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol 2008; 26:2839.</a></li><li><a class="nounderline abstract_t">Heddleston JM, Li Z, Lathia JD, et al. Hypoxia inducible factors in cancer stem cells. Br J Cancer 2010; 102:789.</a></li><li><a class="nounderline abstract_t">Lee HW, Hwang YH, Han JH, et al. High expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with nasopharyngeal cancer. Oral Oncol 2010; 46:209.</a></li><li><a class="nounderline abstract_t">Guillouf C, Rosselli F, Krishnaraju K, et al. p53 involvement in control of G2 exit of the cell cycle: role in DNA damage-induced apoptosis. Oncogene 1995; 10:2263.</a></li><li><a class="nounderline abstract_t">Jiang G, Ren B, Xu L, et al. Survivin may enhance DNA double-strand break repair capability by up-regulating Ku70 in human KB cells. Anticancer Res 2009; 29:223.</a></li><li><a class="nounderline abstract_t">Seiwert TY, Salama JK, Vokes EE. The concurrent chemoradiation paradigm--general principles. Nat Clin Pract Oncol 2007; 4:86.</a></li><li><a class="nounderline abstract_t">Khosravi Shahi P, Fernández Pineda I. Tumoral angiogenesis: review of the literature. Cancer Invest 2008; 26:104.</a></li><li><a class="nounderline abstract_t">Moeller BJ, Dreher MR, Rabbani ZN, et al. Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 2005; 8:99.</a></li><li><a class="nounderline abstract_t">Jorgensen TJ. Enhancing radiosensitivity: targeting the DNA repair pathways. Cancer Biol Ther 2009; 8:665.</a></li><li><a class="nounderline abstract_t">Bussink J, van der Kogel AJ, Kaanders JH. Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol 2008; 9:288.</a></li><li><a class="nounderline abstract_t">Seiwert TY, Cohen EE. Targeting angiogenesis in head and neck cancer. Semin Oncol 2008; 35:274.</a></li><li><a class="nounderline abstract_t">Yu Y, Lee NY. JAVELIN Head and Neck 100: a Phase III trial of avelumab and chemoradiation for locally advanced head and neck cancer. Future Oncol 2019; 15:687.</a></li><li class="breakAll">JAVELIN Head and Neck 100 Trial Discontinued Due to Efficacy Doubts https://www.targetedonc.com/view/javelin-head-and-neck-100-trial-discontinued-due-to-efficacy-doubts.</li><li><a class="nounderline abstract_t">Overgaard J. Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck--a systematic review and meta-analysis. Radiother Oncol 2011; 100:22.</a></li><li><a class="nounderline abstract_t">Brown JM, Wang LH. Tirapazamine: laboratory data relevant to clinical activity. Anticancer Drug Des 1998; 13:529.</a></li><li><a class="nounderline abstract_t">Rischin D, Peters LJ, O'Sullivan B, et al. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol 2010; 28:2989.</a></li><li><a class="nounderline abstract_t">Seiwert TY, Salama JK, Vokes EE. The chemoradiation paradigm in head and neck cancer. Nat Clin Pract Oncol 2007; 4:156.</a></li><li><a class="nounderline abstract_t">Bennett MH, Feldmeier J, Smee R, Milross C. Hyperbaric oxygenation for tumour sensitisation to radiotherapy. Cochrane Database Syst Rev 2012; :CD005007.</a></li><li><a class="nounderline abstract_t">Newbold K, Castellano I, Charles-Edwards E, et al. An exploratory study into the role of dynamic contrast-enhanced magnetic resonance imaging or perfusion computed tomography for detection of intratumoral hypoxia in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2009; 74:29.</a></li><li><a class="nounderline abstract_t">Lapi SE, Voller TF, Welch MJ. Positron Emission Tomography Imaging of Hypoxia. PET Clin 2009; 4:39.</a></li><li><a class="nounderline abstract_t">Rischin D, Fisher R, Peters L, et al. Hypoxia in head and neck cancer: studies with hypoxic positron emission tomography imaging and hypoxic cytotoxins. Int J Radiat Oncol Biol Phys 2007; 69:S61.</a></li><li><a class="nounderline abstract_t">Søvik A, Malinen E, Olsen DR. Strategies for biologic image-guided dose escalation: a review. Int J Radiat Oncol Biol Phys 2009; 73:650.</a></li><li><a class="nounderline abstract_t">Flynn RT, Bowen SR, Bentzen SM, et al. Intensity-modulated x-ray (IMXT) versus proton (IMPT) therapy for theragnostic hypoxia-based dose painting. Phys Med Biol 2008; 53:4153.</a></li><li><a class="nounderline abstract_t">Lin Z, Mechalakos J, Nehmeh S, et al. The influence of changes in tumor hypoxia on dose-painting treatment plans based on 18F-FMISO positron emission tomography. Int J Radiat Oncol Biol Phys 2008; 70:1219.</a></li><li><a class="nounderline abstract_t">Hoff CM, Hansen HS, Overgaard M, et al. The importance of haemoglobin level and effect of transfusion in HNSCC patients treated with radiotherapy--results from the randomized DAHANCA 5 study. Radiother Oncol 2011; 98:28.</a></li><li><a class="nounderline abstract_t">Dunphy FR, Harrison BR, Dunleavy TL, et al. Erythropoietin reduces anemia and transfusions: A randomized trial with or without erythropoietin during chemotherapy. Cancer 1999; 86:1362.</a></li><li><a class="nounderline abstract_t">Dunphy FR, Dunleavy TL, Harrison BR, et al. Erythropoietin reduces anemia and transfusions after chemotherapy with paclitaxel and carboplatin. Cancer 1997; 79:1623.</a></li><li><a class="nounderline abstract_t">Glaser CM, Millesi W, Kornek GV, et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 2001; 50:705.</a></li><li><a class="nounderline abstract_t">Henke M, Laszig R, Rübe C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003; 362:1255.</a></li><li><a class="nounderline abstract_t">Machtay M, Pajak TF, Suntharalingam M, et al. Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03). Int J Radiat Oncol Biol Phys 2007; 69:1008.</a></li><li><a class="nounderline abstract_t">Shenouda G, Zhang Q, Ang KK, et al. Long-term results of radiation therapy oncology group 9903: a randomized phase 3 trial to assess the effect of erythropoietin on local-regional control in anemic patients treated with radiation therapy for squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 2015; 91:907.</a></li><li><a class="nounderline abstract_t">Lambin P, Ramaekers BL, van Mastrigt GA, et al. Erythropoietin as an adjuvant treatment with (chemo) radiation therapy for head and neck cancer. Cochrane Database Syst Rev 2009; :CD006158.</a></li><li><a class="nounderline abstract_t">Overgaard J, Hoff CM, Hansen HS, et al. DAHANCA 10 - Effect of darbepoetin alfa and radiotherapy in the treatment of squamous cell carcinoma of the head and neck. A multicenter, open-label, randomized, phase 3 trial by the Danish head and neck cancer group. Radiother Oncol 2018; 127:12.</a></li><li><a class="nounderline abstract_t">Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008; 299:914.</a></li><li><a class="nounderline abstract_t">Mohyeldin A, Lu H, Dalgard C, et al. Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma. Neoplasia 2005; 7:537.</a></li><li><a class="nounderline abstract_t">Miller CP, Lowe KA, Valliant-Saunders K, et al. Evaluating erythropoietin-associated tumor progression using archival tissues from a phase III clinical trial. Stem Cells 2009; 27:2353.</a></li><li class="breakAll">FDA website available online at http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM109375 (Accessed on October 21, 2011).</li><li><a class="nounderline abstract_t">Le QT, Kim HE, Schneider CJ, et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo-controlled study. J Clin Oncol 2011; 29:2808.</a></li><li><a class="nounderline abstract_t">Henke M, Alfonsi M, Foa P, et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo-controlled trial. J Clin Oncol 2011; 29:2815.</a></li><li><a class="nounderline abstract_t">Jones EL, Oleson JR, Prosnitz LR, et al. Randomized trial of hyperthermia and radiation for superficial tumors. J Clin Oncol 2005; 23:3079.</a></li><li><a class="nounderline abstract_t">Prosnitz LR, Maguire P, Anderson JM, et al. The treatment of high-grade soft tissue sarcomas with preoperative thermoradiotherapy. Int J Radiat Oncol Biol Phys 1999; 45:941.</a></li><li><a class="nounderline abstract_t">van der Zee J, González González D, van Rhoon GC, et al. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group. Lancet 2000; 355:1119.</a></li><li><a class="nounderline abstract_t">Westra A, Dewey WC. Variation in sensitivity to heat shock during the cell-cycle of Chinese hamster cells in vitro. Int J Radiat Biol Relat Stud Phys Chem Med 1971; 19:467.</a></li><li><a class="nounderline abstract_t">TERASIMA T, TOLMACH LJ. Variations in several responses of HeLa cells to x-irradiation during the division cycle. Biophys J 1963; 3:11.</a></li><li><a class="nounderline abstract_t">Gerweck LE, Nygaard TG, Burlett M. Response of cells to hyperthermia under acute and chronic hypoxic conditions. Cancer Res 1979; 39:966.</a></li><li><a class="nounderline abstract_t">Mivechi NF, Miyachi H, Scanlon KJ. Heat radiosensitization and the level of DNA polymerases alpha and beta of human colony-forming unit-granulocyte-macrophage and myeloid leukemias sensitive and resistant to chemotherapeutic agents. Cancer Res 1990; 50:2044.</a></li><li><a class="nounderline abstract_t">Raaphorst GP, Ng CE, Yang DP. Thermal radiosensitization and repair inhibition in human melanoma cells: a comparison of survival and DNA double strand breaks. Int J Hyperthermia 1999; 15:17.</a></li><li><a class="nounderline abstract_t">Brizel DM, Scully SP, Harrelson JM, et al. Radiation therapy and hyperthermia improve the oxygenation of human soft tissue sarcomas. Cancer Res 1996; 56:5347.</a></li><li><a class="nounderline abstract_t">Datta NR, Bose AK, Kapoor HK, Gupta S. Head and neck cancers: results of thermoradiotherapy versus radiotherapy. Int J Hyperthermia 1990; 6:479.</a></li><li><a class="nounderline abstract_t">Valdagni R, Amichetti M. Report of long-term follow-up in a randomized trial comparing radiation therapy and radiation therapy plus hyperthermia to metastatic lymph nodes in stage IV head and neck patients. Int J Radiat Oncol Biol Phys 1994; 28:163.</a></li></ol></div><div id="topicVersionRevision">Topic 3371 Version 33.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21684027" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21684027" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21684027" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16817329" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Radical radiotherapy in head and neck squamous cell carcinoma: an analysis of prognostic and therapeutic factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9165136" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Importance of overall treatment time for the outcome of radiotherapy of advanced head and neck carcinoma: dependency on tumor differentiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16951142" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Tumor cell radiosensitivity is a major determinant of tumor response to radiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17483312" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Influence of tumor cell and stroma sensitivity on tumor response to radiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9869231" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85-27.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15752888" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19289626" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Pretreatment health behaviors predict survival among patients with head and neck squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16587006" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : On the Mechanism of X-Ray Scattering.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17440683" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7546822" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Nicotinamide and other benzamide analogs as agents for overcoming hypoxic cell radiation resistance in tumours. A review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9226314" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16098619" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17883552" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Clinical and biological factors affecting response to radiotherapy in patients with head and neck cancer: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11306467" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16826581" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The relation between hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression with anemia and outcome in surgically treated head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16642001" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Lysyl oxidase is essential for hypoxia-induced metastasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19667273" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Validation of lysyl oxidase as a prognostic marker for metastasis and survival in head and neck squamous cell carcinoma: Radiation Therapy Oncology Group trial 90-03.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19223896" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Treatment regimen determines whether an HIF-1 inhibitor enhances or inhibits the effect of radiation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12182996" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : How fast is repopulation of tumor cells during the treatment gap?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3390344" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The hazard of accelerated tumor clonogen repopulation during radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15446804" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Modelling of post-irradiation accelerated repopulation in squamous cell carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16110017" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11857304" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : p53 and Ki-67 as markers of radioresistance in head and neck carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18511937" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Exploring the role of cancer stem cells in radioresistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16931775" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Successful therapy must eradicate cancer stem cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19249647" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Cancer stem cells and tumor response to therapy: current problems and future prospects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19249644" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Cancer stem cells in solid tumors: an overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16990346" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16488983" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Cancer stem cells: an old idea--a paradigm shift.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17517444" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Pre-treatment number of clonogenic cells and their radiosensitivity are major determinants of local tumour control after fractionated irradiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18539962" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20104230" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Hypoxia inducible factors in cancer stem cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20153243" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : High expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with nasopharyngeal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7784074" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : p53 involvement in control of G2 exit of the cell cycle: role in DNA damage-induced apoptosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19331153" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Survivin may enhance DNA double-strand break repair capability by up-regulating Ku70 in human KB cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17259930" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The concurrent chemoradiation paradigm--general principles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18181052" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Tumoral angiogenesis: review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16098463" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19287209" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Enhancing radiosensitivity: targeting the DNA repair pathways.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18308254" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18544442" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Targeting angiogenesis in head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30461306" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : JAVELIN Head and Neck 100: a Phase III trial of avelumab and chemoradiation for locally advanced head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30461306" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : JAVELIN Head and Neck 100: a Phase III trial of avelumab and chemoradiation for locally advanced head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21511351" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck--a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9755717" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Tirapazamine: laboratory data relevant to clinical activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20479425" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17327856" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The chemoradiation paradigm in head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22513926" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Hyperbaric oxygenation for tumour sensitisation to radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19036529" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : An exploratory study into the role of dynamic contrast-enhanced magnetic resonance imaging or perfusion computed tomography for detection of intratumoral hypoxia in head-and-neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20046923" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Positron Emission Tomography Imaging of Hypoxia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17848298" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Hypoxia in head and neck cancer: studies with hypoxic positron emission tomography imaging and hypoxic cytotoxins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19215819" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Strategies for biologic image-guided dose escalation: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18635895" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Intensity-modulated x-ray (IMXT) versus proton (IMPT) therapy for theragnostic hypoxia-based dose painting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18313529" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The influence of changes in tumor hypoxia on dose-painting treatment plans based on 18F-FMISO positron emission tomography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20970213" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The importance of haemoglobin level and effect of transfusion in HNSCC patients treated with radiotherapy--results from the randomized DAHANCA 5 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10506726" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Erythropoietin reduces anemia and transfusions: A randomized trial with or without erythropoietin during chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9118049" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Erythropoietin reduces anemia and transfusions after chemotherapy with paclitaxel and carboplatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11395239" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14575968" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17716826" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25670542" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Long-term results of radiation therapy oncology group 9903: a randomized phase 3 trial to assess the effect of erythropoietin on local-regional control in anemic patients treated with radiation therapy for squamous cell carcinoma of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19588382" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Erythropoietin as an adjuvant treatment with (chemo) radiation therapy for head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29523409" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : DAHANCA 10 - Effect of darbepoetin alfa and radiotherapy in the treatment of squamous cell carcinoma of the head and neck. A multicenter, open-label, randomized, phase 3 trial by the Danish head and neck cancer group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18314434" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15967106" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19544471" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Evaluating erythropoietin-associated tumor progression using archival tissues from a phase III clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19544471" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Evaluating erythropoietin-associated tumor progression using archival tissues from a phase III clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21670453" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21670447" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15860867" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Randomized trial of hyperthermia and radiation for superficial tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10571201" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : The treatment of high-grade soft tissue sarcomas with preoperative thermoradiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10791373" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5314347" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Variation in sensitivity to heat shock during the cell-cycle of Chinese hamster cells in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13980635" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Variations in several responses of HeLa cells to x-irradiation during the division cycle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34477" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Response of cells to hyperthermia under acute and chronic hypoxic conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2317794" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Heat radiosensitization and the level of DNA polymerases alpha and beta of human colony-forming unit-granulocyte-macrophage and myeloid leukemias sensitive and resistant to chemotherapeutic agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10193754" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Thermal radiosensitization and repair inhibition in human melanoma cells: a comparison of survival and DNA double strand breaks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8968082" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Radiation therapy and hyperthermia improve the oxygenation of human soft tissue sarcomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2198311" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Head and neck cancers: results of thermoradiotherapy versus radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8270437" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Report of long-term follow-up in a randomized trial comparing radiation therapy and radiation therapy plus hyperthermia to metastatic lymph nodes in stage IV head and neck patients.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
